romiplostim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
colony stimulating factors 4996 267639-76-9

Description:

MoleculeDescription

Synonyms:

  • romiplostim
  • nplate
  • AMG-531
  • AMG531
Romiplostim, a member of the TPO mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor (also known as cMpl). The peptibody molecule contains two identical single-chain subunits, each consisting of human immunoglobulin IgG1 Fc domain, covalently linked at the C-terminus to a peptide containing two thrombopoietin receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. Romiplostim is produced by recombinant DNA technology in Escherichia coli.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
30 mcg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2011 PMDA Kyowa Hakko Kirin
Aug. 22, 2008 FDA AMGEN
Feb. 4, 2009 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count abnormal 1942.63 20.53 365 13546 3970 90610566
Platelet count decreased 1567.31 20.53 636 13275 136333 90478203
Therapeutic response decreased 1059.33 20.53 427 13484 89302 90525234
Thrombocytopenia 649.33 20.53 401 13510 208324 90406212
Thrombocytosis 524.07 20.53 136 13775 6865 90607671
Platelet count increased 404.19 20.53 143 13768 20716 90593820
Myelofibrosis 321.88 20.53 69 13842 1498 90613038
Petechiae 320.52 20.53 112 13799 15629 90598907
Splenectomy 294.53 20.53 55 13856 570 90613966
Drug ineffective 279.24 20.53 635 13276 1383663 89230873
Haemorrhage 260.80 20.53 151 13760 69218 90545318
Biopsy bone marrow abnormal 240.39 20.53 41 13870 239 90614297
Bone marrow reticulin fibrosis 202.27 20.53 34 13877 179 90614357
Death 193.71 20.53 290 13621 456261 90158275
Immune thrombocytopenia 190.19 20.53 73 13838 13253 90601283
Myelodysplastic syndrome 164.77 20.53 75 13836 20828 90593708
Deep vein thrombosis 153.90 20.53 121 13790 91499 90523037
Purpura 132.38 20.53 58 13853 14720 90599816
Epistaxis 123.02 20.53 103 13808 85022 90529514
Off label use 111.83 20.53 396 13515 1101856 89512680
Gingival bleeding 97.43 20.53 47 13864 14856 90599680
Hospitalisation 95.91 20.53 108 13803 127992 90486544
Mucosal haemorrhage 93.23 20.53 25 13886 1428 90613108
Evans syndrome 90.81 20.53 19 13892 365 90614171
Chronic lymphocytic leukaemia 81.95 20.53 27 13884 3143 90611393
Drug effective for unapproved indication 80.52 20.53 34 13877 7884 90606652
Pulmonary embolism 79.25 20.53 99 13812 130721 90483815
Vaginal haemorrhage 79.17 20.53 53 13858 31218 90583318
Therapy non-responder 77.35 20.53 100 13811 136604 90477932
Ecchymosis 66.15 20.53 34 13877 12289 90602247
Contusion 59.66 20.53 124 13787 251092 90363444
Haemorrhage intracranial 59.54 20.53 34 13877 15128 90599408
Mucocutaneous haemorrhage 59.34 20.53 11 13900 109 90614427
Cerebral venous sinus thrombosis 56.49 20.53 19 13892 2357 90612179
Mouth haemorrhage 56.13 20.53 27 13884 8474 90606062
Cerebral haemorrhage 54.49 20.53 44 13867 34478 90580058
Heavy menstrual bleeding 52.45 20.53 35 13876 20495 90594041
Bone marrow disorder 51.96 20.53 19 13892 3013 90611523
Cerebral venous thrombosis 49.03 20.53 17 13894 2311 90612225
Infusion related reaction 49.02 20.53 4 13907 416776 90197760
Drug hypersensitivity 48.08 20.53 7 13904 463602 90150934
Melaena 47.95 20.53 41 13870 34756 90579780
Leukocytosis 47.85 20.53 39 13872 30951 90583585
Product preparation error 45.71 20.53 25 13886 10236 90604300
Thrombosis 45.23 20.53 56 13855 73195 90541341
Acute myeloid leukaemia 45.20 20.53 32 13879 20608 90593928
Joint swelling 44.97 20.53 11 13900 503289 90111247
Haematological malignancy 44.51 20.53 11 13900 453 90614083
Rheumatoid arthritis 44.00 20.53 3 13908 362611 90251925
Gastrointestinal haemorrhage 43.36 20.53 61 13850 90187 90524349
White blood cell count increased 39.27 20.53 50 13861 67191 90547345
Leukoerythroblastic anaemia 38.13 20.53 6 13905 19 90614517
Aplastic anaemia 37.26 20.53 24 13887 13245 90601291
Portal vein thrombosis 37.07 20.53 15 13896 3123 90611413
Arthropathy 36.88 20.53 6 13905 366236 90248300
Headache 36.77 20.53 242 13669 862504 89752032
Product use issue 36.57 20.53 4 13907 329915 90284621
Chronic myelomonocytic leukaemia 35.60 20.53 9 13902 407 90614129
Splenomegaly 35.36 20.53 23 13888 12901 90601635
Abdominal discomfort 34.60 20.53 15 13896 477313 90137223
Antiphospholipid syndrome 34.38 20.53 13 13898 2261 90612275
Swelling 34 20.53 11 13900 419047 90195489
Platelet disorder 33.92 20.53 13 13898 2346 90612190
Occupational exposure to product 33.03 20.53 13 13898 2518 90612018
Wound 32.76 20.53 4 13907 302976 90311560
Drug intolerance 32.54 20.53 14 13897 447577 90166959
Bone pain 31.42 20.53 43 13868 61940 90552596
Embolism 31.28 20.53 19 13892 9462 90605074
Embolism arterial 30.80 20.53 10 13901 1111 90613425
Pericarditis 30.64 20.53 3 13908 270148 90344388
Toxicity to various agents 30.63 20.53 4 13907 287842 90326694
Marrow hyperplasia 30.24 20.53 9 13902 750 90613786
Musculoskeletal stiffness 29.53 20.53 5 13906 296527 90318009
Cerebrovascular accident 29.30 20.53 61 13850 123472 90491064
Sudden hearing loss 28.46 20.53 10 13901 1413 90613123
Refusal of treatment by patient 28.41 20.53 15 13896 5723 90608813
Peripheral swelling 28.35 20.53 14 13897 413092 90201444
Lower respiratory tract infection 27.87 20.53 3 13908 250656 90363880
Blood blister 27.40 20.53 11 13900 2244 90612292
Reticulin increased 27.08 20.53 4 13907 7 90614529
Stomatitis 26.55 20.53 5 13906 274693 90339843
Rash maculo-papular 26.40 20.53 32 13879 40901 90573635
Hypersensitivity 26.16 20.53 19 13892 454658 90159878
Rectal haemorrhage 25.94 20.53 46 13865 82698 90531838
Anaemia 25.90 20.53 115 13796 352687 90261849
Sepsis 25.68 20.53 73 13838 179741 90434795
Impaired healing 25.54 20.53 3 13908 234196 90380340
Haemoglobin decreased 25.35 20.53 68 13843 161888 90452648
Antibody test 25.34 20.53 4 13907 13 90614523
Hepatic enzyme increased 25.09 20.53 12 13899 360724 90253812
Intercepted product administration error 24.63 20.53 8 13903 890 90613646
Haematoma 24.33 20.53 30 13881 39018 90575518
Blood smear test abnormal 24.10 20.53 5 13906 92 90614444
Pain 24.00 20.53 76 13835 996265 89618271
Condition aggravated 23.91 20.53 34 13877 595511 90019025
Blister 23.89 20.53 5 13906 254993 90359543
Drug ineffective for unapproved indication 23.45 20.53 39 13872 66605 90547931
Megaloblasts increased 23.35 20.53 3 13908 0 90614536
HCoV-OC43 infection 23.07 20.53 4 13907 26 90614510
Myeloproliferative neoplasm 22.73 20.53 7 13904 655 90613881
Myalgia 22.05 20.53 68 13843 175057 90439479
Bone marrow myelogram abnormal 21.73 20.53 4 13907 38 90614498
Intercepted product preparation error 21.61 20.53 8 13903 1312 90613224
Non-Hodgkin's lymphoma 21.23 20.53 8 13903 1378 90613158
Type 2 diabetes mellitus 21.20 20.53 3 13908 203241 90411295
Ovarian cancer 20.90 20.53 13 13898 6754 90607782
Dyspnoea 20.64 20.53 68 13843 880887 89733649

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count abnormal 1085.70 20.17 244 12180 3405 42605506
Platelet count decreased 822.33 20.17 506 11918 138075 42470836
Therapeutic response decreased 776.00 20.17 319 12105 36693 42572218
Drug ineffective 351.14 20.17 640 11784 629557 41979354
Platelet count increased 321.64 20.17 120 12304 10583 42598328
Bone marrow reticulin fibrosis 318.74 20.17 53 12371 111 42608800
Thrombocytosis 282.76 20.17 89 12335 4686 42604225
Coombs positive haemolytic anaemia 252.59 20.17 61 12363 1174 42607737
Thrombocytopenia 252.43 20.17 293 12131 189986 42418925
Myelodysplastic syndrome 225.98 20.17 117 12307 22628 42586283
Lymphadenitis 209.68 20.17 61 12363 2450 42606461
Myelofibrosis 190.89 20.17 53 12371 1794 42607117
Haemolysis 161.65 20.17 71 12353 9518 42599393
Splenectomy 155.67 20.17 34 12390 409 42608502
Therapeutic product effect decreased 153.32 20.17 111 12313 39039 42569872
Petechiae 149.61 20.17 69 12355 10366 42598545
Immune thrombocytopenia 144.86 20.17 69 12355 11147 42597764
Biopsy bone marrow abnormal 133.84 20.17 28 12396 270 42608641
Haematological malignancy 131.30 20.17 31 12393 539 42608372
Hospitalisation 116.16 20.17 125 12299 74205 42534706
Death 105.37 20.17 338 12086 470847 42138064
Migraine 85.89 20.17 66 12358 25348 42583563
Haemorrhage 84.47 20.17 96 12328 60467 42548444
Deep vein thrombosis 82.89 20.17 107 12317 76850 42532061
Acute myeloid leukaemia 82.31 20.17 61 12363 22195 42586716
Chronic lymphocytic leukaemia 78.92 20.17 35 12389 4794 42604117
Therapy non-responder 78.54 20.17 87 12337 53272 42555639
Migraine with aura 75.27 20.17 22 12402 897 42608014
Off label use 69.69 20.17 367 12057 637968 41970943
Epistaxis 64.37 20.17 88 12336 66738 42542173
Drug interaction 56.66 20.17 6 12418 266993 42341918
Investigation 53.55 20.17 17 12407 918 42607993
Hepatic enzyme increased 52.96 20.17 66 12358 45718 42563193
Toxicity to various agents 51.69 20.17 4 12420 229132 42379779
Gingival bleeding 49.89 20.17 31 12393 8454 42600457
Mouth haemorrhage 47.60 20.17 27 12397 6234 42602677
Ecchymosis 47.30 20.17 29 12395 7723 42601188
Contusion 46.13 20.17 59 12365 41926 42566985
Embolism arterial 42.82 20.17 14 12410 831 42608080
Pulmonary embolism 42.54 20.17 102 12322 119510 42489401
Cellulitis gangrenous 38.13 20.17 10 12414 271 42608640
Bone marrow disorder 37.70 20.17 16 12408 1970 42606941
Infusion related reaction 37.28 20.17 65 12359 60741 42548170
Platelet disorder 36.30 20.17 16 12408 2158 42606753
Myeloproliferative neoplasm 35.57 20.17 12 12412 785 42608126
Evans syndrome 33.92 20.17 10 12414 420 42608491
Cerebrovascular accident 33.61 20.17 82 12342 97078 42511833
Condition aggravated 30.80 20.17 19 12405 260735 42348176
Mesenteric vascular insufficiency 30.55 20.17 7 12417 106 42608805
Antiphospholipid syndrome 30.21 20.17 10 12414 617 42608294
Marrow hyperplasia 29.96 20.17 12 12412 1275 42607636
Therapeutic response delayed 28.87 20.17 10 12414 709 42608202
Non-Hodgkin's lymphoma 28.61 20.17 12 12412 1435 42607476
Reticulin increased 28.56 20.17 4 12420 0 42608911
Mucocutaneous haemorrhage 28.44 20.17 7 12417 146 42608765
Thrombocytopenia neonatal 27.29 20.17 9 12415 549 42608362
Diarrhoea 27.02 20.17 59 12365 460790 42148121
Mucosal haemorrhage 26.15 20.17 12 12412 1778 42607133
Embolism 25.81 20.17 21 12403 8742 42600169
Refusal of treatment by patient 25.35 20.17 17 12407 5274 42603637
Thrombosis 24.95 20.17 59 12365 68452 42540459
Vomiting 24.58 20.17 29 12395 289694 42319217
Product preparation error 24.46 20.17 16 12408 4762 42604149
Bone pain 23.89 20.17 32 12392 23760 42585151
Intercepted product administration error 23.37 20.17 8 12416 547 42608364
Hypotension 22.70 20.17 25 12399 257606 42351305
Acute kidney injury 22.36 20.17 46 12378 367291 42241620
Lymphoma 22.17 20.17 24 12400 14297 42594614
Dyspnoea 21.77 20.17 62 12362 442559 42166352
Gastrointestinal haemorrhage 21.49 20.17 70 12354 97656 42511255
Splenosis 21.42 20.17 3 12421 0 42608911
Leukocytosis 21.19 20.17 34 12390 29674 42579237
White blood cell count increased 21.15 20.17 43 12381 45044 42563867
Protein-losing gastroenteropathy 21.05 20.17 7 12417 438 42608473
Chronic myelomonocytic leukaemia 20.89 20.17 8 12416 755 42608156
Neutropenia 20.36 20.17 113 12311 199318 42409593
Dehydration 20.23 20.17 8 12416 141759 42467152

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count abnormal 2271.17 17.71 453 19321 5829 110563696
Platelet count decreased 1634.85 17.71 802 18972 229641 110339884
Thrombocytosis 723.58 17.71 197 19577 10247 110559278
Therapeutic response decreased 720.50 17.71 349 19425 96150 110473375
Thrombocytopenia 597.44 17.71 495 19279 348390 110221135
Platelet count increased 481.33 17.71 180 19594 26154 110543371
Petechiae 370.73 17.71 144 19630 23173 110546352
Myelofibrosis 360.07 17.71 88 19686 2963 110566562
Bone marrow reticulin fibrosis 298.30 17.71 52 19722 294 110569231
Drug ineffective 282.61 17.71 744 19030 1519796 109049729
Coombs positive haemolytic anaemia 267.36 17.71 61 19713 1516 110568009
Haemorrhage 243.74 17.71 180 19594 106512 110463013
Myelodysplastic syndrome 236.13 17.71 121 19653 37363 110532162
Biopsy bone marrow abnormal 228.71 17.71 44 19730 458 110569067
Splenectomy 210.24 17.71 45 19729 825 110568700
Off label use 203.68 17.71 657 19117 1499528 109069997
Immune thrombocytopenia 197.05 17.71 91 19683 22403 110547122
Lymphadenitis 191.93 17.71 61 19713 5432 110564093
Deep vein thrombosis 171.79 17.71 165 19609 139722 110429803
Haemolysis 171.33 17.71 74 19700 15565 110553960
Epistaxis 164.30 17.71 156 19618 130216 110439309
Death 140.92 17.71 354 19420 698515 109871010
Therapy non-responder 131.27 17.71 151 19623 157156 110412369
Gingival bleeding 127.68 17.71 65 19709 19774 110549751
Purpura 120.51 17.71 67 19707 24321 110545204
Hospitalisation 105.99 17.71 129 19645 142364 110427161
Pulmonary embolism 98.78 17.71 154 19620 214320 110355205
Therapeutic product effect decreased 98.33 17.71 165 19609 244151 110325374
Evans syndrome 94.81 17.71 23 19751 749 110568776
Mucosal haemorrhage 87.08 17.71 29 19745 2991 110566534
Mouth haemorrhage 83.33 17.71 43 19731 13445 110556080
Drug effective for unapproved indication 81.34 17.71 43 19731 14124 110555401
Ecchymosis 75.86 17.71 44 19730 17294 110552231
Acute myeloid leukaemia 73.08 17.71 58 19716 38052 110531473
Contusion 72.66 17.71 141 19633 233220 110336305
Vaginal haemorrhage 70.33 17.71 48 19726 25026 110544499
Mucocutaneous haemorrhage 70.02 17.71 15 19759 276 110569249
Haematological malignancy 69.71 17.71 19 19755 988 110568537
Toxicity to various agents 61.53 17.71 7 19767 480548 110088977
Product preparation error 59.58 17.71 32 19742 10847 110558678
Investigation 57.84 17.71 20 19754 2312 110567213
Migraine with aura 57 17.71 22 19752 3470 110566055
Antiphospholipid syndrome 56.30 17.71 20 19754 2503 110567022
Platelet disorder 55.91 17.71 22 19752 3653 110565872
Marrow hyperplasia 54.80 17.71 18 19756 1778 110567747
Cerebral haemorrhage 53.51 17.71 62 19712 64906 110504619
White blood cell count increased 52.34 17.71 75 19699 96767 110472758
Gastrointestinal haemorrhage 51.48 17.71 100 19674 165418 110404107
Cerebral venous thrombosis 51.29 17.71 20 19754 3242 110566283
Cerebral venous sinus thrombosis 49.98 17.71 19 19755 2876 110566649
Drug interaction 49.62 17.71 14 19760 500169 110069356
Leukocytosis 48.81 17.71 54 19720 53774 110515751
Chronic lymphocytic leukaemia 48.70 17.71 23 19751 5945 110563580
Drug hypersensitivity 48.33 17.71 11 19763 454079 110115446
Joint swelling 46.59 17.71 11 19763 442834 110126691
Haemorrhage intracranial 44.94 17.71 39 19735 28930 110540595
Melaena 44.32 17.71 58 19716 68699 110500826
Bone pain 43.64 17.71 56 19718 65077 110504448
Cerebrovascular accident 42.95 17.71 98 19676 181186 110388339
Condition aggravated 41.69 17.71 42 19732 734794 109834731
Drug ineffective for unapproved indication 40.70 17.71 69 19705 102769 110466756
Reticulin increased 40.28 17.71 6 19768 9 110569516
Leukoerythroblastic anaemia 39.89 17.71 6 19768 10 110569515
Neutralising antibodies positive 39.78 17.71 10 19764 378 110569147
Cellulitis gangrenous 38.85 17.71 10 19764 416 110569109
Product use issue 38.74 17.71 5 19769 311690 110257835
Splenomegaly 38.04 17.71 33 19741 24465 110545060
Autoimmune haemolytic anaemia 36.38 17.71 23 19751 10544 110558981
Wheezing 34.52 17.71 3 19771 255227 110314298
Migraine 34.42 17.71 87 19687 171565 110397960
Headache 34.25 17.71 272 19502 882105 109687420
Dyspnoea 33.46 17.71 95 19679 1106777 109462748
Haemorrhagic diathesis 32.70 17.71 19 19755 7489 110562036
Drug intolerance 32.55 17.71 16 19758 406496 110163029
Mesenteric vascular insufficiency 32.26 17.71 7 19767 137 110569388
Megakaryocytes increased 32.22 17.71 7 19767 138 110569387
Peripheral swelling 32.21 17.71 16 19758 404018 110165507
Blood blister 31.88 17.71 15 19759 3844 110565681
Vomiting 31.47 17.71 73 19701 910602 109658923
Myeloproliferative neoplasm 30.83 17.71 11 19763 1394 110568131
Arthropathy 30.50 17.71 7 19767 287515 110282010
Neutropenia 30.33 17.71 140 19634 374480 110195045
Swelling 29.36 17.71 13 19761 351028 110218497
Thrombosis 28.26 17.71 61 19713 108601 110460924
Intercepted product administration error 27.66 17.71 9 19765 863 110568662
Bone marrow disorder 27.64 17.71 14 19760 4209 110565316
Musculoskeletal stiffness 27.41 17.71 8 19766 279814 110289711
Heavy menstrual bleeding 27.36 17.71 23 19751 16342 110553183
Therapeutic response delayed 27.20 17.71 10 19764 1380 110568145
Upper respiratory tract inflammation 27.18 17.71 14 19760 4357 110565168
Abdominal discomfort 26.60 17.71 19 19755 393839 110175686
Wound 26.32 17.71 5 19769 234432 110335093
Haemolytic anaemia 26.24 17.71 25 19749 20895 110548630
Anti-platelet antibody positive 26.08 17.71 7 19767 343 110569182
Pain 25.95 17.71 86 19688 954869 109614656
Sudden hearing loss 25.71 17.71 11 19763 2258 110567267
Lower respiratory tract infection 25.62 17.71 6 19768 243100 110326425
Dry mouth 25.35 17.71 3 19771 199945 110369580
Antibody test 25.23 17.71 4 19770 11 110569514
Cerebral infarction 24.91 17.71 38 19736 51800 110517725
Intercepted medication error 24.73 17.71 9 19765 1207 110568318
Paroxysmal nocturnal haemoglobinuria 24.72 17.71 7 19767 419 110569106
Chronic myeloid leukaemia 24.61 17.71 13 19761 4260 110565265
Conjunctival haemorrhage 24.25 17.71 15 19759 6618 110562907
Refusal of treatment by patient 23.87 17.71 17 19757 9477 110560048
Red blood cell abnormality 23.52 17.71 8 19766 880 110568645
Embolism 23.41 17.71 21 19753 16268 110553257
Portal vein thrombosis 23.40 17.71 15 19759 7043 110562482
Blister 23.21 17.71 6 19768 227370 110342155
Bone marrow myelogram abnormal 23.09 17.71 5 19769 97 110569428
Hypersensitivity 22.98 17.71 23 19751 403975 110165550
Megakaryocytes abnormal 22.58 17.71 5 19769 108 110569417
Pruritus 22.24 17.71 44 19730 581516 109988009
Chronic myelomonocytic leukaemia 22.11 17.71 8 19766 1055 110568470
Sepsis 21.96 17.71 116 19658 327230 110242295
Neutralising antibodies 21.74 17.71 4 19770 32 110569493
Type 2 diabetes mellitus 21.64 17.71 3 19771 177229 110392296
Leukoerythroblastosis 21.53 17.71 6 19768 339 110569186
Diarrhoea 21.49 17.71 118 19656 1139387 109430138
Intercepted product preparation error 21.39 17.71 14 19760 6806 110562719
Aplastic anaemia 21.37 17.71 24 19750 24284 110545241
Anaemia 21.35 17.71 169 19605 546917 110022608
Rectal haemorrhage 21.22 17.71 58 19716 119775 110449750
Unevaluable event 21.16 17.71 38 19736 59189 110510336
Stomatitis 21.08 17.71 11 19763 270231 110299294
Ischaemic stroke 20.89 17.71 31 19743 41232 110528293
Haemoglobin decreased 20.89 17.71 94 19680 248633 110320892
Fibromyalgia 20.62 17.71 3 19771 170906 110398619
Neoplasm malignant 20.40 17.71 29 19745 37114 110532411
Osteoarthritis 20.28 17.71 4 19770 182619 110386906
Haematoma 20.23 17.71 37 19737 58439 110511086
HCoV-OC43 infection 19.76 17.71 4 19770 55 110569470
Megaloblasts increased 19.59 17.71 3 19771 6 110569519
Antibody test positive 19.42 17.71 10 19764 3110 110566415
Sinusitis 19.14 17.71 15 19759 296673 110272852
Oxygen saturation decreased 18.38 17.71 3 19771 156979 110412546
Asthma 18.35 17.71 11 19763 250280 110319245
Platelet production decreased 18.27 17.71 3 19771 11 110569514
Bradycardia 18.14 17.71 3 19771 155514 110414011
Platelet glycoprotein gene mutation 18.06 17.71 3 19771 12 110569513
Hypotension 18.05 17.71 42 19732 523807 110045718
Acute leukaemia 17.82 17.71 8 19766 1841 110567684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02BX04 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Other systemic hemostatics
FDA MoA N0000175968 Thrombopoietin Receptor Agonists
FDA PE N0000175969 Increased Megakaryocyte Maturation
FDA PE N0000175970 Increased Platelet Production
FDA EPC N0000175973 Thrombopoietin Receptor Agonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs
avatrombopagcarbazochromeconcizumabeltrombopagemicizumabetamsylatefitusiranfostamatiniblusutrombopagmarstacimab-hncq

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic idiopathic thrombocytopenic purpura indication 13172003
Aplastic anemia indication 306058006 DOID:12449




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thrombopoietin receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D08990 KEGG_DRUG
4028106 VUID
N0000177934 NUI
4028106 VANDF
CHEBI:749606 CHEBI
CHEMBL1201832 ChEMBL_ID
C488777 MESH_SUPPLEMENTAL_RECORD_UI
6974 IUPHAR_LIGAND_ID
DB05332 DRUGBANK_ID
805452 RXNORM
147787 MMSL
25808 MMSL
d07320 MMSL
012794 NDDF
439122000 SNOMEDCT_US
441077008 SNOMEDCT_US
C2364481 UMLSCUI
8587 INN_ID
135449332 PUBCHEM_CID
GN5XU2DXKV UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nplate HUMAN PRESCRIPTION DRUG LABEL 1 55513-221 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 ug SUBCUTANEOUS BLA 31 sections
Nplate HUMAN PRESCRIPTION DRUG LABEL 1 55513-222 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 ug SUBCUTANEOUS BLA 31 sections
Nplate HUMAN PRESCRIPTION DRUG LABEL 1 55513-223 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 125 ug SUBCUTANEOUS BLA 31 sections